Home > News > Foreword – US Ophthalmic Review, 2015;8(1):9
Cataract Surgery
Read Time: 2 mins

Foreword – US Ophthalmic Review, 2015;8(1):9

Published Online: March 20th 2015 US Ophthalmic Review, 2015;8(1):9
Authors: Mark OM Tso
Quick Links:
Article
Article Information
Article:

Welcome to the Spring edition of US Ophthalmic Review, which covers new advances in cataract, glaucoma, cornea, and
retina sub specialities.

In a timely update, Potvin et al. discuss the latest knowledge on the LenSx® femtosecond laser system. Lambert et al. compare contact
lens and intraocular lens correction of monocular aphakia during infancy and a global perspective on immediately sequential bilateral
cataract surgery is provided by Arshinoff.

A meta-analysis is presented by Blanton of six excimer laser platforms for safety and efficacy in myopic laser-assisted in situ
keratomileusis while Melles et al. discuss the safety of treatment options for advanced keratoconus. A promising advance is reviewed
by Reinstein, concerning specifically small incision lenticule extraction; an all-femtosecond laser, keyhole, flapless procedure.
Glaucoma inflicts the most common form of optic neuropathy, a major cause of blindness worldwide. When to perform incisional
glaucoma surgery is a challenging question addressed by Panarelli and ophthalmic imaging tools used to detect glaucoma progression
are the topic tackled by Wollstein et al. Ahmad et al. shed slight on the concept of pharmacologic trabeculectomy; and new agents are
being investigated that modulate the aqueous humor outflow through the trabecular meshwork. Recent breakthroughs in stem cell
therapy and challenges for glaucoma are discussed by Chen et al.

Despite their convenience for patients, major challenges remain in the use of eye drops to treat retina disease. However, as Gibson
et al. uncover, improved technologies may enable sustained topical drug delivery for retinal therapy, with reasonable side-effect
and cost-effectiveness profiles. A new treatment option is reviewed by Kuppermann, ocriplasmin for the treatment of symptomatic
vitreomacular adhesion/traction, and a telemedicine system for identifying eyes with retinopathy or prematurity is reported by Quinn.
Finally, innovation for developing countries is the topic of a symposium reported by Feldman from the most recent American Academy
of Ophthalmology’s Annual Meeting.

US Ophthalmic Review would like to thank the expert authors and the editorial board for their continuous support and guidance. We
hope you find this edition useful and insightful.

Article Information:

Further Resources

Share this Article
Related Content In Cataract Surgery
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72